ChartMill assigns a Buy % Consensus number of 85% to VRDN. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-03 | William Blair | Initiate | Outperform |
| 2025-11-24 | Truist Securities | Initiate | Buy |
| 2025-11-06 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-04 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-21 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-08-07 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-08-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-07 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-07 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-08-06 | Needham | Maintains | Buy -> Buy |
| 2025-05-20 | Needham | Reiterate | Buy -> Buy |
| 2025-05-07 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-05-07 | Needham | Maintains | Buy -> Buy |
| 2025-05-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-07 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-04-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-07 | Needham | Reiterate | Buy -> Buy |
| 2024-12-19 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2024-12-17 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-12-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-05 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-11-25 | TD Cowen | Initiate | Buy |
| 2024-11-25 | Needham | Reiterate | Buy -> Buy |
| 2024-11-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-13 | Needham | Reiterate | Buy -> Buy |
| 2024-10-28 | Needham | Reiterate | Buy -> Buy |
| 2024-09-26 | BTIG | Maintains | Buy -> Buy |
| 2024-09-19 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-09-13 | RBC Capital | Maintains | Outperform -> Outperform |
23 analysts have analysed VRDN and the average price target is 40.55 USD. This implies a price increase of 29.54% is expected in the next year compared to the current price of 31.3.
The consensus rating for VIRIDIAN THERAPEUTICS INC (VRDN) is 85.2174 / 100 . This indicates that analysts generally have a positive outlook on the stock.